Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

BCT.TO Relative to the S&P 500

BCT.TO Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the BriaCell Therapeutics Corp. (TSE:BCT.TO) seasonal charts above shows that a Buy Date of December 27 and a Sell Date of April 9 has resulted in a geometric average return of 2.74% above the benchmark rate of the S&P 500 Total Return Index over the past 15 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 15 years by an average of 102.74% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

To download BCT.TO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: BCT.TO